Sabatino DArchi
Overview
Explore the profile of Sabatino DArchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DArchi S, Carnassale B, Sanchez A, Accetta C, Belli P, De Lauretis F, et al.
J Pers Med
. 2025 Jan;
15(1).
PMID: 39852228
B3 breast lesions, classified as lesions of uncertain malignant potential, present a significant diagnostic and therapeutic challenge due to their heterogeneous nature and variable risk of progression to malignancy. These...
2.
Franceschini G, DArchi S, Di Leone A, Masetti R
Updates Surg
. 2025 Jan;
PMID: 39831929
No abstract available.
3.
DArchi S, Carnassale B, Accetta C, Belli P, De Lauretis F, Di Guglielmo E, et al.
J Clin Med
. 2025 Jan;
14(1.
PMID: 39797153
: B3 breast lesions, characterized by uncertain malignant potential, pose a significant challenge for clinicians. With the increasing use of preoperative biopsies, there is a need for careful management strategies,...
4.
Scardina L, Carnassale B, Di Leone A, Sanchez A, Biondi E, Moschella F, et al.
J Clin Med
. 2024 Jul;
13(13).
PMID: 38999531
: Breast cancer in young women aged < 40 years is rare and often aggressive with less favorable survival rates. The lack of systematic screening, later stage at diagnosis, and...
5.
Franco A, Di Leone A, Conti M, Fabi A, Carbognin L, Terribile A, et al.
J Pers Med
. 2023 Aug;
13(8).
PMID: 37623530
Introduction: The selection of surgery post-neoadjuvant chemotherapy (NACT) is difficult and based on surgeons' expertise. The aim of this study was to create a post-NEoadjuvant Score System (pNESSy) to choose...
6.
Scardina L, Di Leone A, Magno S, Franco A, Biondi E, Sanchez A, et al.
Front Oncol
. 2022 Dec;
12:995442.
PMID: 36483034
Introduction: Paget's disease (PD) represents 1%-3% of all breast cancers and mostly occurs in postmenopausal women. Multiple studies have confirmed that breast-conserving surgery (BCS) followed by radiotherapy is a safe...
7.
Mason E, Di Leone A, Franco A, DArchi S, Rianna C, Sanchez A, et al.
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428718
Oncoplastic level II breast-conserving surgery (OPS2) allows for wider excisions than standard breast-conserving surgery, but the literature on this technique in the treatment of DCIS is scarce. This study compares...
8.
DAngelo A, Trombadori C, Caprini F, Cicero S, Longo V, Ferrara F, et al.
Curr Oncol
. 2022 Nov;
29(11):8468-8474.
PMID: 36354727
In this retrospective study we share our single-center experience using a magnetic seed for the preoperative localization of non-palpable breast lesions. Patients who underwent a preoperative localization with Magseed (Endomagnetics,...
9.
Scardina L, Di Leone A, Biondi E, Carnassale B, Sanchez A, DArchi S, et al.
J Pers Med
. 2022 Sep;
12(9).
PMID: 36143318
Background: Conservative mastectomy with immediate prosthetic breast reconstruction (IPBR) is an oncologically accepted technique that offers improved esthetic results and patient quality of life. Traditionally, implants have been placed in...
10.
Di Leone A, Franco A, Terribile D, Magno S, Fabi A, Sanchez A, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267583
Oncoplastic surgery level II techniques (OPSII) are used in patients with operable breast cancer. There is no evidence regarding their safety and efficacy after neoadjuvant chemotherapy (NAC). The aim of...